Inhibikase Therapeutics Inc (IKT)

NASDAQ
1.650
-0.120(-6.78%)
After Hours
1.750
+0.100(+6.061%)
- Real-time Data
  • Volume:
    542,485
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1.540 - 1.770

IKT Overview

Prev. Close
1.77
Day's Range
1.54-1.77
Revenue
3.27M
Open
1.75
52 wk Range
1.54-11.8
EPS
-0.8
Volume
542,485
Market Cap
41.51M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
313,843
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
25,155,198
Next Earnings Date
Mar 31, 2022
What is your sentiment on Inhibikase Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Inhibikase Therapeutics Inc Company Profile

Employees
3

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellSell
Technical IndicatorsBuyStrong BuyStrong SellStrong SellSell
SummaryNeutralNeutralStrong SellStrong SellSell
  • anyone?
    0
    • What s up 3..03
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.